Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex

Abstract Ankyrins are cellular repeat proteins, which can be genetically modified to randomize amino-acid residues located at defined positions in each repeat unit, and thus create a potential binding surface adaptable to macromolecular ligands. From a phage-display library of artificial ankyrins, we have isolated AnkGAG1D4, a trimodular ankyrin which binds to the HIV-1 capsid protein N-terminal domain (NTDCA) and has an antiviral effect at the late steps of the virus life cycle. In this study, the determinants of the AnkGAG1D4-NTDCA interaction were analyzed using peptide scanning in competition ELISA, capsid mutagenesis, ankyrin crystallography and molecular modeling. We determined the AnkGAG1D4 structure at 2.2 Å resolution, and used the crystal structure in molecular docking with a homology model of HIV-1 capsid. Our results indicated that NTDCA alpha-helices H1 and H7 could mediate the formation of the capsid-AnkGAG1D4 binary complex, but the interaction involving H7 was predicted to be more stable than with H1. Arginine-18 (R18) in H1, and R132 and R143 in H7 were found to be the key players of the AnkGAG1D4-NTDCA interaction. This was confirmed by R-to-A mutagenesis of NTDCA, and by sequence analysis of trimodular ankyrins negative for capsid binding. In AnkGAG1D4, major interactors common to H1 and H7 were found to be S45, Y56, R89, K122 and K123. Collectively, our ankyrin-capsid binding analysis implied a significant degree of flexibility within the NTDCA domain of the HIV-1 capsid protein, and provided some clues for the design of new antivirals targeting the capsid protein and viral assembly.

[1]  Daniel C. Desrosiers,et al.  The ankyrin repeat as molecular architecture for protein recognition , 2004, Protein science : a publication of the Protein Society.

[2]  Zhiping Weng,et al.  Performance of ZDOCK and ZRANK in CAPRI rounds 13–19 , 2010, Proteins.

[3]  Chun Tang,et al.  Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. , 2007, Journal of molecular biology.

[4]  Praphan Phanuphak,et al.  A Novel Immunodominant CD8+ T Cell Response Restricted by a Common HLA-C Allele Targets a Conserved Region of Gag HIV-1 Clade CRF01_AE Infected Thais , 2011, PloS one.

[5]  J. Herz,et al.  Topological mapping of complement component C9 by recombinant DNA techniques suggests a novel mechanism for its insertion into target membranes. , 1987, The EMBO journal.

[6]  Pierre Boulanger,et al.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain , 2008, Virology Journal.

[7]  Christophe Briand,et al.  Designed ankyrin repeat protein binders for the crystallization of AcrB: plasticity of the dominant interface. , 2011, Journal of structural biology.

[8]  Wesley I. Sundquist,et al.  Structure of the Amino-Terminal Core Domain of the HIV-1 Capsid Protein , 1996, Science.

[9]  Chatchai Tayapiwatana,et al.  Appraisal of translocation pathways for displaying ankyrin repeat protein on phage particles. , 2010, Protein expression and purification.

[10]  D. Harrich,et al.  A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells. , 2013, Human gene therapy.

[11]  Z. Weng,et al.  A novel shape complementarity scoring function for protein‐protein docking , 2003, Proteins.

[12]  Wesley I. Sundquist,et al.  Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein , 2003, Journal of Virology.

[13]  H. Göttlinger,et al.  The HIV-1 assembly machine. , 2001, AIDS.

[14]  D. Baltimore,et al.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus , 1989, Cell.

[15]  G Fischer,et al.  Cyclophilin A complexed with a fragment of HIV-1 gag protein: insights into HIV-1 infectious activity. , 1997, Structure.

[16]  J. Saint-Remy,et al.  Epitope mapping: a new method for biological evaluation and immunotoxicology. , 1997, Toxicology.

[17]  Wesley I. Sundquist,et al.  Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein , 2012, Journal of Virology.

[18]  M. Tsai,et al.  Ankyrin repeat: a unique motif mediating protein-protein interactions. , 2006, Biochemistry.

[19]  Alasdair C. Steven,et al.  Visualization of a Missing Link in Retrovirus Capsid Assembly , 2009, Nature.

[20]  Andreas Plückthun,et al.  Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. , 2007, Structure.

[21]  C. Aiken,et al.  Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization , 2010, Journal of Virology.

[22]  Oliver T. Fackler,et al.  Nef from Human Immunodeficiency Virus Type 1F12 Inhibits Viral Production and Infectivity , 2001, Journal of Virology.

[23]  E. Freed,et al.  HIV-1 gag proteins: diverse functions in the virus life cycle. , 1998, Virology.

[24]  E. Freed,et al.  Viral Late Domains , 2002, Journal of Virology.

[25]  Mark Yeager,et al.  The structural biology of HIV assembly. , 2008, Current opinion in structural biology.

[26]  E. Freed,et al.  Human immunodeficiency virus type 1 assembly, release, and maturation. , 2007, Advances in pharmacology.

[27]  Eric Barklis,et al.  Antiviral inhibition of the HIV-1 capsid protein. , 2003, Journal of molecular biology.

[28]  Manuel C. Peitsch,et al.  SWISS-MODEL: an automated protein homology-modeling server , 2003, Nucleic Acids Res..

[29]  Manuel Simon,et al.  Designed ankyrin repeat proteins (DARPins) from research to therapy. , 2012, Methods in enzymology.

[30]  Ywh-Min Tzou,et al.  Structure of a monomeric mutant of the HIV-1 capsid protein. , 2011, Biochemistry.

[31]  P Boulanger,et al.  Morphopoietic determinants of HIV-1 Gag particles assembled in baculovirus-infected cells. , 1998, Virology.

[32]  Ariberto Fassati,et al.  Multiple roles of the capsid protein in the early steps of HIV-1 infection. , 2012, Virus research.

[33]  Jean-François Mercier,et al.  Discovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid Complexes , 2013, Antimicrobial Agents and Chemotherapy.

[34]  J. Nieman,et al.  HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention , 2010, PLoS pathogens.

[35]  W. Sundquist,et al.  Assembly and analysis of conical models for the HIV-1 core. , 1999, Science.

[36]  J. Flanagan,et al.  Retroviral capsid assembly: a role for the CA dimer in initiation. , 2009, Journal of molecular biology.

[37]  Wesley I. Sundquist,et al.  Assembly Properties of the Human Immunodeficiency Virus Type 1 CA Protein , 2004, Journal of Virology.

[38]  Torsten Schaller,et al.  CPSF6 Defines a Conserved Capsid Interface that Modulates HIV-1 Replication , 2012, PLoS pathogens.

[39]  Andreas Plückthun,et al.  Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.

[40]  Anchi Cheng,et al.  Structure of Full-Length HIV-1 CA: A Model for the Mature Capsid Lattice , 2007, Cell.

[41]  J. Darlix,et al.  Biomedicine and Diseases: Review¶Assembling the human immunodeficiency virus type 1 , 2002, Cellular and Molecular Life Sciences CMLS.

[42]  Jean-François Mercier,et al.  Monitoring Binding of HIV‐1 Capsid Assembly Inhibitors Using 19F Ligand‐and 15N Protein‐Based NMR and X‐ray Crystallography: Early Hit Validation of a Benzodiazepine Series , 2013, ChemMedChem.

[43]  Pierre Boulanger,et al.  The 3-O-(3’,3’-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells , 2007, Antiviral therapy.

[44]  Jeremy Luban,et al.  Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. , 2009, The Journal of clinical investigation.

[45]  Chatchai Tayapiwatana,et al.  Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients , 2008, BMC biotechnology.

[46]  M. V. Regenmortel,et al.  Structural and functional approaches to the study of protein antigenicity. , 1989, Immunology today.

[47]  S. Smerdon,et al.  The ankyrin repeat: a diversity of interactions on a common structural framework. , 1999, Trends in biochemical sciences.

[48]  Pierre Boulanger,et al.  Baculovirus display of single chain antibody (scFv) using a novel signal peptide , 2010, BMC biotechnology.

[49]  Mark Yeager,et al.  X-Ray Structures of the Hexameric Building Block of the HIV Capsid , 2009, Cell.

[50]  Frank Heinrich,et al.  HIV-1 Gag extension: conformational changes require simultaneous interaction with membrane and nucleic acid. , 2011, Journal of molecular biology.

[51]  J. Lenstra,et al.  Mapping of viral epitopes with prokaryotic expression products , 2005, Archives of Virology.

[52]  Andreas Plückthun,et al.  Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins* , 2005, Journal of Biological Chemistry.

[53]  M. Khan,et al.  Identification of Dominant Negative Human Immunodeficiency Virus Type 1 Vif Mutants That Interfere with the Functional Inactivation of APOBEC3G by Virus-Encoded Vif , 2010, Journal of Virology.

[54]  A. Engelman,et al.  The structural biology of HIV-1: mechanistic and therapeutic insights , 2012, Nature Reviews Microbiology.

[55]  Kunio Nagashima,et al.  The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. , 2010, Virology.

[56]  Joe Lewis,et al.  Residues in the HIV-1 Capsid Assembly Inhibitor Binding Site Are Essential for Maintaining the Assembly-competent Quaternary Structure of the Capsid Protein* , 2008, Journal of Biological Chemistry.

[57]  Markus G Grütter,et al.  Chaperone-assisted crystallography with DARPins. , 2008, Structure.

[58]  Áine McKnight,et al.  A whole genome screen for HIV restriction factors , 2011, Retrovirology.

[59]  Li Li,et al.  RDOCK: Refinement of rigid‐body protein docking predictions , 2003, Proteins.

[60]  Karin Musier-Forsyth,et al.  Diverse interactions of retroviral Gag proteins with RNAs. , 2011, Trends in biochemical sciences.

[61]  Z. Weng,et al.  ZDOCK: An initial‐stage protein‐docking algorithm , 2003, Proteins.

[62]  Andreas Plückthun,et al.  A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.

[63]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[64]  Barbara Müller,et al.  A peptide inhibitor of HIV-1 assembly in vitro , 2005, Nature Structural &Molecular Biology.

[65]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[66]  Pierre Boulanger,et al.  Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein , 2011, Retrovirology.

[67]  Kristof Theys,et al.  Functional conservation of HIV-1 Gag: implications for rational drug design , 2013, Retrovirology.

[68]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[69]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[70]  M Rau,et al.  Nucleocapsid protein of human immunodeficiency virus as a model protein with chaperoning functions and as a target for antiviral drugs. , 2000, Advances in pharmacology.

[71]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[72]  Andreas Plückthun,et al.  Structural and functional analysis of phosphorylation-specific binders of the kinase ERK from designed ankyrin repeat protein libraries , 2012, Proceedings of the National Academy of Sciences.

[73]  Patrick Amstutz,et al.  CD4-Specific Designed Ankyrin Repeat Proteins Are Novel Potent HIV Entry Inhibitors with Unique Characteristics , 2008, PLoS pathogens.